AI English summary of an SEC filing — figures as filed
IDEXX Laboratories IDXXThe company said in this amended filing (Amendment No. 1) that it is correcting the range for projected comparable operating profit margin expansion for 2024, from 70 to 100 basis points to 30 to 60 basis points. It said all other information in the original earnings release is unchanged.
Key points
AI summaryThe company said in this amended filing (Amendment No. 1) that it is correcting the range for projected comparable operating profit margin expansion for 2024, from 70 to 100 basis points to 30 to 60 basis points. It said all other information in the original earnings release is unchanged.
The company adjusted its full-year 2024 revenue guidance to $3,865 million to $3,890 million (reported growth of 5.5% to 6.2%), down from $3,885 million to $3,945 million previously, a reduction of $38 million at the midpoint. The company said it reflected trends in U.S. veterinary clinic visits and demand.
IDEXX said it narrowed its full-year 2024 EPS outlook to $10.37 to $10.53 from the prior $10.31 to $10.59, while keeping the midpoint unchanged. It said 2024 EPS results include a negative impact of $0.56 from a discrete litigation expense accrual recorded in the Q2.
The company reported revenue of $976 million for Q3 2024, up 7% as reported and 6% organically, and EPS of $2.80, up 11% as reported and 12% on a comparable basis. It said operating margin was 31.2%, higher by 110 basis points as reported and 100 basis points on a comparable basis.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Correction to 2024 Comparable Operating Profit Margin Expansion Range
The company said in this amended filing (Amendment No. 1) that it is correcting the range for projected comparable operating profit margin expansion for 2024, from 70 to 100 basis points to 30 to 60 basis points. It said all other information in the original earnings release is unchanged.
Source · Based on the filing body and exhibits
Full-Year 2024 Revenue Guidance Adjusted
The company adjusted its full-year 2024 revenue guidance to $3,865 million to $3,890 million (reported growth of 5.5% to 6.2%), down from $3,885 million to $3,945 million previously, a reduction of $38 million at the midpoint. The company said it reflected trends in U.S. veterinary clinic visits and demand.
Source · Based on the filing body and exhibits
Full-Year 2024 EPS Outlook Range Narrowed
IDEXX said it narrowed its full-year 2024 EPS outlook to $10.37 to $10.53 from the prior $10.31 to $10.59, while keeping the midpoint unchanged. It said 2024 EPS results include a negative impact of $0.56 from a discrete litigation expense accrual recorded in the Q2.
Source · Based on the filing body and exhibits
Q3 2024 Revenue, Operating Margin and EPS Results
The company reported revenue of $976 million for Q3 2024, up 7% as reported and 6% organically, and EPS of $2.80, up 11% as reported and 12% on a comparable basis. It said operating margin was 31.2%, higher by 110 basis points as reported and 100 basis points on a comparable basis.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…